

## **Australia Biotech Invest 2016**

(Held in Melbourne, Australia on 26-27 October 2016)

### **Company Spotlight Presentations**

(To view presentation, please click the presenting company's name)

<b>Presenting Company</b>	<b>Profile</b>	<b>Presenter</b>
<a href="#"><b><u>Adalta Limited</u></b> <b>[1AD]</b></a>	Developing drug treating idiopathic pulmonary fibrosis and other fibrotic diseases	MD Samantha Cobb
<a href="#"><b><u>Adherium Limited</u></b> <b>[ADR]</b></a>	A global leader in digital health technologies for chronic respiratory conditions including COPD and asthma	Group CEO Garth Sutherland
<a href="#"><b><u>LBT Innovations Limited</u></b> <b>[LBT]</b></a>	A medical technology company that develops the latest intelligent imaging technology and interpretative software to improve the efficiency and quality of clinical diagnosis across a wide spectrum of healthcare applications	CEO Brent John Barnes
<a href="#"><b><u>Novogen Limited</u></b> <b>[NRT]</b></a>	Oncology-focused drug development company with two proprietary drug discovery platforms, providing first-in-class agents with potential application across a range of oncology indications	CEO Dr James Garner
<a href="#"><b><u>Opal Biosciences Limited</u></b></a>	An innovative player in infectious disease treatment, committed to tackling the serious global health threat in antibiotic resistance and targets treatment of human infection: a high growth, commercially attractive market segment.	MD Julie Phillips

<p><b><u>Phosphagenics Limited</u></b> <b>[POH]</b></p>	<p>Discovers and develops new ways to enhance the delivery, effectiveness, and/or tolerability of proven pharmaceutical, consumer and animal health products</p>	<p>MD &amp; CEO Dr Ross Murdoch</p>
<p><b><u>Proteomics International Laboratories Ltd</u></b> <b>[PIQ]</b></p>	<p>Applying its disruptive technology platform to study the structure and function of proteins, focusing on the discovery of new diagnostic biomarkers</p>	<p>MD Dr Richard Lipscombe</p>
<p><b><u>Regeneus Limited</u></b> <b>[RGS]</b></p>	<p>A clinical stage regenerative medicine company developing a portfolio of innovative cellular therapies for unmet medical needs in the human and animal health markets</p>	<p>CEO John Martin</p>